Year: 2021
BERGENBIO PRESENTS ENCOURAGING UPDATED PRELIMINARY DATA FROM PHASE II STUDY IN RELAPSED AML PATIENTS AT EHA VIRTUAL MEETING
Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML…
Read MoreBERGENBIO ANNOUNCES LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021
Bergen, Norway, 10 June 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stagebiopharmaceutical company developing novel,…
Read MoreBERGENBIO RECEIVED FDA FAST-TRACK DESIGNATION FOR BEMCENTINIB / ANTI-PD-(L)1 COMBINATION IN NSCLC
First recognition by a regulator of AXL-positive patients as a target population Bergen, Norway, 08…
Read MoreBERGENBIO TO PRESENT PRECLINICAL DATA ON TILVESTAMAB IN CHRONIC KIDNEY DISEASE AT ERA-EDTA VIRTUAL CONGRESS 2021
Bergen, Norway, 07 June 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing…
Read MoreBERGENBIO PRESENTS DATA FROM PHASE I/II BEMCENTINIB/ERLOTINIB COMBINATION TRIAL IN NSCLC AT ASCO MEETING
Bergen, Norway, 04 June 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing…
Read MoreBERGENBIO TO PRESENT AT ABGSC SEMINAR
Bergen, Norway, 21 May 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stagebiopharmaceutical company developing novel,…
Read More
